Dengue serotype cross-reactive, anti-E protein antibodies confound specific immune memory for 1 year after infection

Frontiers in Immunology

Volumn 5, Issue AUG, 2014, Pages

  Toh, Ying Xiu ^a   Gan, Victor ^b   Balakrishnan, Thavamalar ^a   Zuest, Roland ^a   Poidinger, Michael ^a   Wilson, Solomonraj ^a   Appanna, Ramapraba ^a   Thein, Tun Linn ^b   Ong, Adrian Kheng Yeow ^b   Ng, Lee Ching ^c   Leo, Yee Sin ^b,d,e   Fink, Katja ^a  

^a AGENCY FOR SCIENCE   (Singapore)

^b TAN TOCK SENG HOSPITAL   (Singapore)

^c NATIONAL ENVIRONMENT AGENCY   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Antibodies; B cells; Cross reactive; Dengue; Longitudinal studies; Plasmablasts; Vaccines; Viral infection

Indexed keywords

EID: 84940346947     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00388     Document Type: Article

References (48)

1. Simmons CP, Farrar JJ, Nguyen VV, Wills B. Dengue. N Engl J Med (2012) 366:1423-32. doi: 10.1056/NEJMra1110265
2. WHO. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. Geneva: TDR/World Health Organization (2009).
3. Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, Vaughn DW, et al. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: how alterations in assay conditions impact performance. Am J Trop Med Hyg (2009) 81:825-33. doi:10.4269/ajtmh.2009.08-0625
4. Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC. A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog (2011) 7:e1002111. doi:10.1371/journal.ppat.1002111
5. Adams B, Holmes EC, Zhang C, Mammen MP Jr, Nimmannitya S, Kalayanarooj S, et al. Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok. Proc Natl Acad Sci U S A (2006) 103:14234-9. doi:10.1073/pnas.0602768103
6. Hubert B, Halstead SB. Dengue 1 virus and dengue hemorrhagic fever, French Polynesia, 2001. Emerg Infect Dis (2009) 15:1265-70. doi:10.3201/eid1508.081500
7. Zompi S, Montoya M, Pohl MO, Balmaseda A, Harris E. Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans. PLoS Negl Trop Dis (2012) 6:e1568. doi:10.1371/journal.pntd.0001568
8. Montoya M, Gresh L, Mercado JC, Williams KL, Vargas MJ, Gutierrez G, et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis (2013) 7:e2357. doi:10.1371/journal.pntd.0002357
9. Olkowski S, Forshey BM, Morrison AC, Rocha C, Vilcarromero S, Halsey ES, et al. Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis (2013) 208:1026-33. doi:10.1093/infdis/jit273
10. Anderson KB, Gibbons RV, Cummings DA, Nisalak A, Green S, Libraty DH, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis (2014) 209:360-8. doi:10.1093/infdis/jit436
11. Reich NG, Shrestha S, King AA, Rohani P, Lessler J, Kalayanarooj S, et al. Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. J R Soc Interface (2013) 10:20130414. doi:10.1098/rsif.2013.0414
12. Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg (1952) 1:30-50.
13. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell (2002) 108:717-25. doi:10.1016/S0092-8674(02)00660-8
14. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 8:271-83. doi:10.1016/j.chom.2010.08.007
15. Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, et al. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol (2010) 84:9227-39. doi:10.1128/JVI.01087-10
16. Junjhon J, Edwards TJ, Utaipat U, Bowman VD, Holdaway HA, Zhang W, et al. Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J Virol (2010) 84:8353-8. doi:10.1128/JVI.00696-10
17. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science (2010) 328:745-8. doi:10.1126/science.1185181
18. Rodenhuis-Zybert IA, Van Der Schaar HM, Voorham DSJM, Van Der Ende-Metselaar H, Lei HY, Wilschut J, et al. Immature dengue virus: a veiled pathogen? PLoS Pathog (2010) 6:e1000718. doi:10.1371/journal.ppat.1000718
19. de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A, et al. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis (2011) 5:e1188. doi:10.1371/journal.pntd.0001188
20. Xu M, Hadinoto V, Appanna R, Joensson K, Toh YX, Balakrishnan T, et al. Plasmablasts generated during repeated dengue infection are virus glycoprotein-specific and bind to multiple virus serotypes. J Immunol (2012) 189:5877-85. doi:10.4049/jimmunol.1201688
21. Lai CY, Tsai WY, Lin SR, Kao CL, Hu HP, King CC, et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol (2008) 82:6631-43. doi:10.1128/JVI.00316-08
22. Lai CY, Williams KL, Wu YC, Knight S, Balmaseda A, Harris E, et al. Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis (2013) 7:e2451. doi:10.1371/journal.pntd.0002451
23. Wahala WM, Huang C, Butrapet S, White L, De Silva AM. Recombinant dengue type 2 viruses with altered E protein domain III epitopes are efficiently neutralized by human immune sera. J Virol (2012) 86:4019-23. doi:10.1128/JVI.06871-11
24. Williams KL, Wahala WM, Orozco S, De Silva AM, Harris E. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology (2012) 429:12-20. doi:10.1016/j.virol.2012.03.003
25. Low JG, Ooi EE, Tolfvenstam T, Leo YS, Hibberd ML, Ng LC, et al. Early Dengue infection and outcome study (EDEN) - study design and preliminary findings. Ann Acad Med Singapore (2006) 35:783-9.
26. Lai YL, Chung YK, Tan HC, Yap HF, Yap G, Ooi EE, et al. Cost-effective real-time reverse transcriptase PCR (RT-PCR) to screen for Dengue virus followed by rapid single-tube multiplex RT-PCR for serotyping of the virus. J Clin Microbiol (2007) 45:935-41. doi:10.1128/JCM.01258-06
27. Umashankar M, Sanchez-San Martin C, Liao M, Reilly B, Guo A, Taylor G, et al. Differential cholesterol binding by class II fusion proteins determines membrane fusion properties. J Virol (2008) 82:9245-53. doi:10.1128/JVI.00975-08
28. Vratskikh O, Stiasny K, Zlatkovic J, Tsouchnikas G, Jarmer J, Karrer U, et al. Dissection of antibody specificities induced by yellow Fever vaccination. PLoS Pathog (2013) 9:e1003458. doi:10.1371/journal.ppat.1003458
29. Schreiber MJ, Holmes EC, Ong SH, Soh HS, Liu W, Tanner L, et al. Genomic epidemiology of a dengue virus epidemic in urban Singapore. J Virol (2009) 83:4163-73. doi:10.1128/JVI.02445-08
30. McBride W, Vasudevan S. Relationship of a dengue 2 isolate from Townsville, 1993, to international isolates. Comm Dis Intelligence (1995) 19:522-3.
31. Chen L, Liu W, Lai S, Li Y, Wang X, Zhang H. Insulin resistance, serum visfatin, and adiponectin levels are associated with metabolic disorders in chronic hepatitis C virus-infected patients. Eur J Gastroenterol Hepatol (2013) 25:935-41. doi:10.1097/MEG.0b013e32835fa988
32. Lee PD, Mukherjee S, Edeling MA, Dowd KA, Austin SK, Manhart CJ, et al. The Fc region of an antibody impacts the neutralization of West Nile viruses in different maturation states. J Virol (2013) 87:13729-40. doi:10.1128/JVI.02340-13
33. Puschnik A, Lau L, Cromwell EA, Balmaseda A, Zompi S, Harris E. Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans. PLoS Negl Trop Dis (2013) 7:e2274. doi:10.1371/journal.pntd.0002274
34. Gordon A, Kuan G, Mercado JC, Gresh L, Aviles W, Balmaseda A, et al. The Nicaraguan pediatric dengue cohort study: incidence of inapparent and symptomatic dengue virus infections, 2004-2010. PLoS Negl Trop Dis (2013) 7:e2462. doi:10.1371/journal.pntd.0002462
35. Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol (2005) 3:13-22. doi:10.1038/nrmicro1067
36. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A (2012) 109:7439-44. doi:10.1073/pnas.1200566109
37. McBride WJ, Mullner H, Labrooy JT, Wronski I. The 1993 dengue 2 epidemic in North Queensland: a serosurvey and comparison of hemagglutination inhibition with an ELISA. Am J Trop Med Hyg (1998) 59:457-61.
38. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, De Silva AM. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology (2009) 392:103-13. doi:10.1016/j.virol.2009.06.037
39. Ito M, Takasaki T, Yamada K, Nerome R, Tajima S, Kurane I. Development and evaluation of fluorogenic TaqMan reverse transcriptase PCR assays for detection of dengue virus types 1 to 4. J Clin Microbiol (2004) 42:5935-7. doi:10.1128/JCM.42.12.5935-5937.2004
40. Arpin C, Banchereau J, Liu YJ. Memory B cells are biased towards terminal differentiation: a strategy that may prevent repertoire freezing. J Exp Med (1997) 186:931-40. doi:10.1084/jem.186.6.931
41. Balakrishnan T, Bela-Ong DB, Toh YX, Flamand M, Devi S, Koh MB, et al. Dengue virus activates polyreactive, natural IgG B cells after primary and secondary infection. PLoS One (2011) 6:e29430. doi:10.1371/journal.pone.0029430
42. Wrammert J, Onlamoon N, Akondy RS, Perng GC, Polsrila K, Chandele A, et al. Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. J Virol (2012) 86:2911-8. doi:10.1128/JVI.06075-11
43. Teoh EP, Kukkaro P, Teo EW, Lim AP, Tan TT, Yip A, et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med (2012) 4:139ra183. doi:10.1126/scitranslmed.3003888
44. Messer WB, De Alwis R, Yount BL, Royal SR, Huynh JP, Smith SA, et al. Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc Natl Acad Sci U S A (2014) 111:1939-44. doi:10.1073/pnas.1317350111
45. Tricou V, Minh NN, Farrar J, Tran HT, Simmons CP. Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue. PLoS Negl Trop Dis (2011) 5:e1309. doi:10.1371/journal.pntd.0001309
46. Xu W, Joo H, Clayton S, Dullaers M, Herve MC, Blankenship D, et al. Macrophages induce differentiation of plasma cells through CXCL10/IP-10. J Exp Med (2012) 209:1813-23. doi:10.1084/jem.20112142
47. Kwissa M, Nakaya HI, Onlamoon N, Wrammert J, Villinger F, Perng GC, et al. Dengue virus infection induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation. Cell Host Microbe (2014) 16:115-27. doi:10.1016/j.chom.2014.06.001
48. Garcia-Bates TM, Cordeiro MT, Nascimento EJ, Smith AP, De Melo SKM, Mcburney SP, et al. Association between magnitude of the virus-specific plasmablast response and disease severity in dengue patients. J Immunol (2013) 190:80-7. doi:10.4049/jimmunol.1103350